DNTH - Company ID 0001690585
The table below shows Dianthus Therapeutics, Inc. /DE/'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.04M | $6.24M | $2.83M | $6.42M | $1.48M | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $145.64M | $83.11M | $32.84M | $29.38M | $12.61M | $50.62M |
| SG&A |
Dianthus Therapeutics, Inc. /DE/ reported annual revenue of $2.04M for fiscal year 2025. That is down 67.3% from $6.24M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $34.33M |
| $24.99M |
| $18.16M |
| $6.74M |
| $1.96M |
| $28.09M |
| Operating income | -$177.93M | -$101.86M | -$48.17M | -$29.70M | -$13.09M | -$78.70M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -$13.11M | -$74.94M |
| EPS (diluted) | -$4.20 | -$2.55 | -$8.45 | -$32.57 | -$15.01 | -$1.71 |